MAGE-3 (267-282)

MAGE-3 (267-282) is a synthetic peptide fragment derived from the melanoma-associated antigen 3 (MAGE-3) protein, corresponding to amino acid residues 267 through 282. As a member of the MAGE protein family, this peptide holds significant importance in immunological and cancer research, particularly due to its role in antigen presentation and immune recognition. Its well-defined sequence and immunogenic properties make it a valuable tool for investigating molecular mechanisms underlying tumor antigenicity, T-cell recognition, and peptide-MHC interactions. The ability to synthesize and manipulate such defined peptide segments enables researchers to dissect complex biological processes and develop innovative approaches in immunology and molecular oncology.

Epitope Mapping: MAGE-3 (267-282) is widely utilized in epitope mapping studies to identify and characterize T-cell epitopes within the MAGE-3 protein. By employing this peptide in in vitro assays, researchers can systematically evaluate its interaction with specific human leukocyte antigen (HLA) molecules and determine the peptide's capacity to be recognized by cytotoxic T lymphocytes. Such investigations are crucial for elucidating immune recognition patterns and for the rational design of immunological assays targeting tumor-associated antigens.

Immunogenicity Assessment: The peptide serves as a robust model for evaluating T-cell responses in various immunological settings. In ex vivo and in vitro assays, it is used to stimulate peripheral blood mononuclear cells (PBMCs) or isolated T-cell populations to assess antigen-specific activation, cytokine production, and proliferation. This application provides valuable insights into the immunogenic potential of MAGE-3-derived sequences and supports the development of immune monitoring protocols in cancer immunology research.

Peptide-MHC Binding Studies: Researchers frequently employ this peptide to investigate peptide-MHC class I binding affinities and specificities. Using binding assays and structural analyses, the interaction between MAGE-3 (267-282) and different HLA alleles can be characterized, aiding in the prediction and validation of immunodominant epitopes. These studies contribute to a deeper understanding of antigen processing and presentation pathways, which are fundamental to vaccine and immunotherapeutic research.

Synthetic Peptide Controls: As a chemically defined peptide, MAGE-3 (267-282) is often incorporated as a positive control in peptide-based immunoassays, including ELISPOT, flow cytometry, and tetramer staining protocols. Its reproducible immunogenic properties ensure assay reliability and facilitate the calibration and validation of experimental systems designed to detect antigen-specific T-cell responses.

Structural and Biophysical Analysis: The defined sequence and purity of this peptide enable its use in structural biology and biophysical research. Techniques such as circular dichroism spectroscopy, NMR, and X-ray crystallography can be applied to study its conformational properties, stability, and interactions with other biomolecules. These analyses provide fundamental data for understanding peptide structure-function relationships and inform the rational design of novel peptide analogs or mimetics for research purposes.

1. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

2. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

3. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

4. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis